Structure Therapeutics (GPCR): Can Upcoming Obesity Trial Catalysts Help Regain Its Form?

Shares of Structure Therapeutics Inc. (GPCR) are trading at a 48% discount to their 52-week high of $94.90 recorded last December, as the company awaits a couple of clinical trial catalysts this quarter.